ID   GL261
AC   CVCL_Y003
SY   Glioma 261; GLIOMA 261; Glioma-261; GL-261
DR   BTO; BTO:0006483
DR   BCRJ; 0299
DR   ChEMBL-Cells; CHEMBL4483160
DR   ChEMBL-Targets; CHEMBL4483239
DR   DSMZ; ACC-802
DR   DSMZCellDive; ACC-802
DR   NCI-DTP; Glioma 261
DR   PRIDE; PXD000589
DR   PRIDE; PXD008733
DR   PubChem_Cell_line; CVCL_Y003
DR   Wikidata; Q27547979
RX   PubMed=16734735;
RX   PubMed=23248259;
RX   PubMed=23686484;
RX   PubMed=25894527;
RX   PubMed=30084848;
RX   PubMed=30524896;
WW   https://en.wikipedia.org/wiki/Glioma_261
CC   Doubling time: ~100-120 hours (DSMZ=ACC-802).
CC   Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Omics: Cell surface proteome.
CC   Omics: Deep exome analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Misspelling: GI261; Note=Occasionally.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21938; Mouse glioblastoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 05-10-23; Version: 15
//
RX   PubMed=16734735; DOI=10.1111/j.1349-7006.2006.00208.x;
RA   Szatmari T., Lumniczky K., Desaknai S., Trajcevski S., Hidvegi E.J.,
RA   Hamada H., Safrany G.;
RT   "Detailed characterization of the mouse glioma 261 tumor model for
RT   experimental glioblastoma therapy.";
RL   Cancer Sci. 97:546-553(2006).
//
RX   PubMed=23248259; DOI=10.4049/jimmunol.1201557;
RA   Ohlfest J.R., Andersen B.M., Litterman A.J., Xia J.-Z., Pennell C.A.,
RA   Swier L.E., Salazar A.M., Olin M.R.;
RT   "Vaccine injection site matters: qualitative and quantitative defects
RT   in CD8 T cells primed as a function of proximity to the tumor in a
RT   murine glioma model.";
RL   J. Immunol. 190:613-620(2013).
//
RX   PubMed=23686484; DOI=10.4049/jimmunol.1203539;
RA   Litterman A.J., Zellmer D.M., Grinnen K.L., Hunt M.A., Dudek A.Z.,
RA   Salazar A.M., Ohlfest J.R.;
RT   "Profound impairment of adaptive immune responses by alkylating
RT   chemotherapy.";
RL   J. Immunol. 190:6259-6268(2013).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=30084848; DOI=10.1038/sdata.2018.157;
RA   Schuster H., Shao W.-G., Weiss T., Pedrioli P.G.A., Roth P., Weller M.,
RA   Campbell D.S., Deutsch E.W., Moritz R.L., Planz O., Rammensee H.-G.,
RA   Aebersold R., Caron E.;
RT   "A tissue-based draft map of the murine MHC class I immunopeptidome.";
RL   Sci. Data 5:180157-180157(2018).
//
RX   PubMed=30524896; DOI=10.1080/2162402X.2018.1501137;
RA   Genoud V., Marinari E., Nikolaev S.I., Castle J.C., Bukur V.,
RA   Dietrich P.-Y., Okada H., Walker P.R.;
RT   "Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint
RT   blockade in SB28 and GL261 mouse glioma models.";
RL   OncoImmunology 7:e1501137.1-e1501137.10(2018).
//